FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having high expressions of PD-L1 (>50%) and no changes in EGFR or [...]